Zonisamide Therapy Reduces Metabolic Consequences and Diminishes Nonalcoholic Fatty Liver Disease in Patients with Epilepsy
Antiepileptic drugs that can reduce aberrant metabolism are beneficial for patients. Zonisamide (ZNS) is a chemical with antiepileptic and antioxidant activities. Here, we evaluate the efficacy of ZNS therapy on reducing obesity and decreasing risks of vascular diseases and hepatic steatosis. Clinic...
Main Authors: | Chi-Ren Huang, Hung-Yi Chuang, Nai-Ching Chen, Shu-Fang Chen, Chung-Yao Hsu, Yao-Chung Chuang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/15/3380 |
Similar Items
-
Safety and Efficacy of Zonisamide in Refractory Epilepsy Patients: Clinical Experience from a Tertiary Center
by: Songül ŞENADIM, et al.
Published: (2018-04-01) -
Immune‐mediated polyarthritis and anterior uveitis secondary to zonisamide administration in a dog with refractory epilepsy
by: Paula Baya, et al.
Published: (2024-03-01) -
Evaluation of antiseizure medications including zonisamide in feline idiopathic epilepsy at a referral hospital in Japan
by: Shino Yoshida, et al.
Published: (2023-07-01) -
ZONEGRAN. NEW IN EVIDENTIAL PHARMACOTHERAPY OF EPILEPSY: OPPORTUNITIES AND EXPECTATIONS
by: I. G. Rudakova
Published: (2016-05-01) -
Bioequivalence of Different Formulations of Zonisamide Oral Suspensions: A Short Review
by: Stević I, et al.
Published: (2023-11-01)